PA
PTGX icon

Profund Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Profund Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98M Sell
16,118
-6,749
-30% -$705K 0.05% 203
2026
Q1 		$2.41M Sell
22,867
-2,707
-11% -$240K 0.09% 161
2025
Q4 		$2.23M Buy
25,574
+7,417
+41% +$607K 0.07% 196
2025
Q3 		$1.21M Sell
18,157
-917
-5% -$52.1K 0.04% 287
2025
Q2 		$1.05M Buy
19,074
+7,515
+65% +$361K 0.04% 289
2025
Q1 		$559K Sell
11,559
-9,090
-44% -$381K 0.02% 435
2024
Q4 		$797K Buy
20,649
+566
+3% +$24.7K 0.03% 343
2024
Q3 		$904K Buy
20,083
+5,554
+38% +$224K 0.03% 346
2024
Q2 		$503K Sell
14,529
-22,946
-61% -$672K 0.02% 492
2024
Q1 		$1.08M Buy
37,475
+9,585
+34% +$261K 0.04% 339
2023
Q4 		$640K Sell
27,890
-30,826
-53% -$539K 0.03% 441
2023
Q3 		$979K Buy
58,716
+6,933
+13% +$135K 0.05% 288
2023
Q2 		$1.43M Buy
51,783
+22,983
+80% +$575K 0.08% 224
2023
Q1 		$662K Buy
+28,800
New +$484K 0.04% 419

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Profund Advisors's PTGX Position: Q2 2026 in Review

Profund Advisors reduced its Protagonist Therapeutics (PTGX) stake by 30% in Q2 2026, selling an estimated $705K and leaving 16,118 shares worth $1.98M. The position accounts for 0.05% of the portfolio, ranked #203.

Profund Advisors first reported a position in PTGX in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.41M in Q1 2026. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Profund Advisors held 16,118 shares of Protagonist Therapeutics worth $1.98M as of Q2 2026.
  • Profund Advisors sold 6,749 Protagonist Therapeutics shares in Q2 2026, an estimated $705K.
  • Protagonist Therapeutics made up 0.05% of Profund Advisors's portfolio in Q2 2026, its #203 holding.
  • Profund Advisors first reported a position in Protagonist Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's Protagonist Therapeutics position peaked at $2.41M in Q1 2026.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.